ClinicalTrials.gg
RecruitingNCT05905172Updated Jun 4, 2025

Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

A Phase 3 interventional study of Hydronidone capsules and The placebo capsules in Liver Fibrosis, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Recruiting at 23 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Planned enrollment
33rd of 127
248 · median 120
Started
2023
with 15 others
Phase 3
9 of 214
4 open now
Primary completion
2028-06
later than 56 of 72 live
Registered
150th of 214
by date
Lead sponsor
6 of 214
Beijing Continent Pharmaceutical Co, Ltd.

Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 33rd largest by planned enrollment of the 127 interventional ones that give a count, is one of 16 that started in 2023, is one of 9 in phase 3, reaches primary completion later than 56 of the 72 other live ones, and was the 150th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

This study is a Phase IIIb extension trial following the "A Randomized, Double-blind, Placebo-controlled, Multicenter, Entecavir-based, Phase III Clinical Trial of Hydronidone Capsule in the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B".

The main objective of this study is to evaluate the effectiveness and the safety of hydronidone capsules for long-term treatment of patients with chronic viral hepatitis B liver fibrosis.

Read the detailed description

Nowadays, there is no satisfactory treatment and drug for liver fibrosis, so the etiology treatment of liver fibrosis and cirrhosis is the most important treatment. However, the etiology and treatment can not completely prevent the progression of liver fibrosis, and liver cirrhosis and liver cancer still occur after antiviral treatment. Although some drugs in domestic and foreign clinical trials have reported the effect of treating liver fibrosis, there is no recognized effective chemical drugs or biological agents against liver fibrosis. According to the available evidence, hydronidone capsules can effectively reduce the severity of liver fibrosis, which is expected to further reduce the risk of clinical endpoint events. Since the clinical benefit from the improvement of liver fibrosis usually takes a long time to observe, this trial takes an extended treatment approach to continuously evaluate the clinical benefit of subjects undergoing long-term treatment with hydronidone capsules in patients with liver fibrosis.

This study is a Phase IIIb extension trial following the "A Randomized, Double-blind, Placebo-controlled, Multicenter, Entecavir-based, Phase III Clinical Trial of Hydronidone Capsule in the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B". Subjects who have completed the Phase III, placebo-controlled design, double-blind, can enter the study and continue treatment according to the original treatment protocol.The aim is to evaluate the effectiveness and the safety of hydronidone capsules for long-term treatment of patients with chronic viral hepatitis B liver fibrosis.

The test group received hydronidone capsules three times a day at a daily dose of 270 mg and oral medication half an hour before the meal. The control group received placebo capsules three times a day, half an hour before the meal.Both the test and control groups received entecavir antiviral therapy as basic treatment, once daily at 0.5 mg each, by fasting oral administration. If the subject is not suitable for entecavir, the investigator will decide on the corresponding antiviral treatment according to the subject's specific condition. Discontinuation criteria for entecavir: According to the Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 edition), the American Association for the Study of Liver Disease (AASLD) and the European Association for Liver Disease (EASL) management guidelines.

Visit examination items: clinical laboratory tests (routine ALT) every 6 months (for ALT and AST, additional tests as appropriate), HBVDNA, hepatitis B, transient elastography examination, etc. In order to improve subject compliance, the investigator may increase or reduce the examination frequency or items, and at least 1 year to reducing the frequency. Additional according to the actual situation

03

Conditions studied

  • Liver Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participate in the Phase III trial of this project (Protocol Number: KDN-F351- 202101 ,ClinicalTrials.gov ID: NCT05115942 ), complete the main treatment course and the last visit;
  • Before the trial, the subject understood the nature, significance, possible benefits, possible inconvenience and potential dangers of the trial, volunteered to participate in the clinical trial, was able to communicate well with the investigator, comply with the requirements of the whole study, and signed a written .

Exclusion criteria

Exclusion Criteria:

  • One of any clinical endpoints occurred during the phase III trial (Note: for non cirrhotic patients, Clinical endpoints include progression to cirrhosis,decompensated cirrhosis complications [ascites, esophagogastric vein rupture and bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, hepatic encephalopathy, portal vein thrombosis and cirrhotic cardiomyopathy], hepatocellular carcinoma, liver transplantation or liver disease related death / all-cause death; For patients with liver cirrhosis, Clinical endpoints include complications of decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, or liver disease-related death / all-cause death);
  • Patients with malignant tumors other than hepatocellular carcinoma and with an expected survival period of less than 1 year;
  • Any opinion of the investigator that may affect the subject to provide or follow the trial protocol, or participation in the trial may affect the trial results or their own safety.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Hydronidone group

    Patients were given three capsules of hydronidone three times a day for 5 years.

    Drug: Hydronidone capsules

  • Placebo comparator
    The placebo group

    Patients were given three capsules of placebo three times a day for 5 years.

    Drug: The placebo capsules

Interventions

  • After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 5 years.

    Also known as: F351

  • DrugThe placebo capsules

    After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.

    Also known as: N

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of clinical endpoint events (defined as the occurrence of any clinical endpoint event).

    For non-cirrhotic patients, clinical endpoints include progression to cirrhosis, decompensated cirrhosis complications \[ascites, esophagogastric vein rupture and bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, portal vein thrombosis and cirrhotic cardiomyopathy, etc.\], hepatocellular carcinoma, liver transplantation or liver disease-related death / all-cause death; for patients with cirrhosis, clinical endpoints include occurrence of decompensated cirrhosis complications, hepatocellular carcinoma, liver transplantation or liver disease-related death or all-cause death.

    Time frame: 5years

07

Study locations

23 of 23 sites recruiting
  • Beijing Ditan Hospital Capital Medical University
    Beijing, Beijing 100020, China
    Recruiting
    • Wen Xie · Contact
  • Shanghai General Hospital,Shanghai Jiao Tong University
    Shanghai, Shanghai 201620, China
    Recruiting
  • Beijing youan hospital, the capital of the capital
    Beijing, China
    Recruiting
    • Sujun Zheng · Contact
  • Tsinghua Changgeng Hospital, Beijing
    Beijing, China
    Recruiting
    • Yuan Huang · Contact
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, China
    Recruiting
    • Wei Li · Contact
  • The Second Xiangya Hospital, Central South University
    Changsha, China
    Recruiting
    • Yongfang Jiang · Contact
  • Xiangya Hospital, Central South University
    Changsha, China
    Recruiting
    • Yan Huang · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
    Recruiting
    • Yongguo Li · Contact
  • Three Gorges Hospital affiliated to Chongqing University
    Chongqing, China
    Recruiting
    • Xuan An · Contact
  • Guizhou Provincial People's Hospital
    Guizhou, China
    Recruiting
    • Xinhua Luo · Contact
  • Hangzhou Xixi Hospital (Hangzhou Sixth People's Hospital)
    Hangzhou, China
    Recruiting
    • Jianfeng Bao · Contact
  • Henan Provincial People's Hospital
    Henan, China
    Recruiting
    • Jia Shang · Contact
  • Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University
    Luzhou, China
    Recruiting
    • Jing Wang · Contact
  • Nanchang Ninth Hospital (Nanchang Central Hospital)
    Nanchang, China
    Recruiting
    • Long Xu · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
    Recruiting
    • Xiaoping Wu · Contact
  • The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)
    Nanjing, China
    Recruiting
    • Jun Li · Contact
  • Ningbo Huamei Hospital, University of Chinese Academy of Sciences
    Ningbo, China
    Recruiting
    • Liyun Fu · Contact
  • Huashan Hospital affiliated to Fudan University
    Shanghai, China
    Recruiting
    • Jiming Zhang · Contact
  • Shenzhen Third People's Hospital
    Shenzhen, China
    Recruiting
    • Qingxian Cai · Contact
  • The First Affiliated Hospital of Xinxiang Medical College
    Xinxiang, China
    Recruiting
    • Xinwen Song · Contact
  • Yanbian University Affiliated Hospital
    Yanbian, China
    Recruiting
    • Ning Chen · Contact
  • Zhenjiang Third People's Hospita
    Zhenjiang, China
    Recruiting
    • Youwen Tan · Contact
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, China
    Recruiting
    • Yawen Luo · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jun 2028, 58 months after the start.

Of 25 phase 3 interventional studies under Liver Cirrhosis, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 82. This study's planned 58 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Jun 15, 2023
StartActual
Aug 12, 2023
Primary completionEst.
Jun 20, 2028
CompletionEst.
Oct 20, 2028
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05905172
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Aug 12, 2023
Primary completion
Jun 20, 2028 (estimated)
Completion
Oct 20, 2028 (estimated)
Last update
Jun 4, 2025

Study contacts

Ling Zhang, Dr
Contact
zhangling@bjcontinent.com
+86-13501209210
Lungen Lu, Dr
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Jun Cheng, Dr
principal investigator · Beijing Ditan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydronidone

Start the discussion